Alzheimer's disease (AD) is characterized by cognitive impairment and the presence of
neurofibrillary tangles and senile plaques in the brain. Neurofibrillary tangles are composed …

Current possibilities of Alzheimer's disease (AD) treatment are very limited and are based on
administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or N …

Abstract A number of N-(2-(1H-indol-3-yl) ethyl)-2-oxo-2H-chromene-3-carboxamides were
synthesized and tested against AChE and BuChE. The in vitro assessment of the …

Background: We previously showed that a water extract of the medicinal plant Centella
asiatica (CAW) attenuates amyloid-ß (Aß)-induced cognitive deficits in vivo, and prevents Aß …

Healthy brain aging and the problems of dementia and Alzheimer's disease (AD) are a
global concern. Beyond 60 years of age, most, if not everyone, will experience a decline in …

BC200 is a long noncoding RNA expressed at high levels in the Alzheimer's disease (AD),
and blocking of BC200 by siRNA is assumed to be an effective method for various disease …

Alzheimer's disease (AD) is the most common dementia affecting one in nine people over
65. Only a handful of small-molecule drugs and the anti-β amyloid (Aβ) antibody …

Memantine non-competitively blocks the N-methyl-D-aspartate receptor in order to inhibit
beta-amyloid (Aβ) secretion, and has been used to treat moderate-to-severe Alzheimer's …

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers
are very productive. The review on Drugs interacting with Enzymes was accepted in August …

Despite the massive investment in Alzheimer's disease (AD), there are still no disease-
modifying treatments (DMTs) for AD. One major reason is attributed to the limitation of …